Esperion Therapeutics, Inc. (LON:0IIM)
1.041
+0.100 (10.65%)
At close: Jun 3, 2025
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
660.88K GBP
Profits / Employee
-390.11K GBP
Market Cap
163.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Esperion Therapeutics News
- 24 days ago - Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - GlobeNewsWire
- 27 days ago - Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 27 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - HLS Therapeutics Announces Q1 2025 Financial Results - Benzinga
- 4 weeks ago - Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - GlobeNewsWire
- 4 weeks ago - Esperion Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga